Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Resources
    • Voices
  • Advertise
  • SUBSCRIBE

Watson Confirms Development Agreement with Natco for Generic Revlimid

By Pharmaceutical Processing | December 7, 2010

Watson Pharmaceuticals, Inc. and Natco Pharma Limited today
confirmed an exclusive, U.S.
development and license agreement, to develop and commercialize lenalidomide 5,
10, 15 and 25 mg tablets. The companies also confirmed that Natco has filed an
Abbreviated New Drug Application (ANDA) with the FDA seeking approval to market
its lenalidomide 5, 10, 15 and 25 mg product. Natco’s lenalidomide tablets are
generic versions of Celgene’s Revlimid  Tablets.

Based on available information, the companies believe that
Natco may be the “first applicant” to file an ANDA for the 5, 10, 15
and 25 mg generic versions of Revlimid and, should the ANDA be approved, may be
entitled to 180 days of generic market exclusivity. Upon successful
commercialization, Watson and Natco will share net profits on sales. Other terms
of the agreement have not been disclosed. Watson will assume responsibility for
ongoing regulatory, legal, and commercial expenses related to Natco’s
lenalidomide product.

Related Articles Read More >

Great Point Partners logo.
Great Point Partners acquires majority stake in Eutecma to fuel sustainable cold chain growth
Driving success in fast-paced high-tech pharma construction projects
This is a photo of the Fujifilm Diosynth Biotechnologies plant under construction in Holly Springs, North Carolina.
Fujifilm, Regeneron ink $3B U.S. manufacturing agreement
This is the logo of Johnson & Johnson.
J&J breaks ground on $2B manufacturing facility in North Carolina
“ppw
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news, technologies, and developments in Pharmaceutical Processing.

DeviceTalks Tuesdays

DeviceTalks Tuesdays

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Pharmaceutical Processing World
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Drug Discovery & Development
  • DeviceTalks
  • MassDevice
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • Medical Design Sourcing
  • Medtech100 Index
  • R&D 100 Awards

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Resources
    • Voices
  • Advertise
  • SUBSCRIBE